Overview
NICE is unable to make a recommendation about the use in the NHS of eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy. This is because Novartis did not provide an evidence submission.
Last reviewed: 27 January 2016
Next review: We will review this decision if the company decides to make a submission